Pfizer (PFE) Position Boosted by Roosevelt Investment Group Inc; Genworth Finl (GNW) Shareholder Saba Capital Management LP Has Decreased Its Position

February 23, 2018 - By Vivian Currie

Roosevelt Investment Group Inc increased its stake in Pfizer Inc (PFE) by 16.85% based on its latest 2017Q3 regulatory filing with the SEC. Roosevelt Investment Group Inc bought 69,374 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 481,090 shares of the health care company at the end of 2017Q3, valued at $17.18 million, up from 411,716 at the end of the previous reported quarter. Roosevelt Investment Group Inc who had been investing in Pfizer Inc for a number of months, seems to be bullish on the $213.04 billion market cap company. The stock decreased 0.06% or $0.02 during the last trading session, reaching $35.74. About 22.75M shares traded or 4.47% up from the average. Pfizer Inc. (NYSE:PFE) has declined 2.76% since February 23, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Boaz Weinstein decreased its stake in Genworth Finl Inc (GNW) by 3.31% based on its latest 2017Q3 regulatory filing with the SEC. Saba Capital Management Lp sold 122,173 shares as the company’s stock declined 8.54% while stock markets rallied. The hedge fund run by Boaz Weinstein held 3.57 million shares of the life insurance company at the end of 2017Q3, valued at $13.75M, down from 3.69M at the end of the previous reported quarter. Saba Capital Management Lp who had been investing in Genworth Finl Inc for a number of months, seems to be less bullish one the $1.42B market cap company. The stock decreased 2.06% or $0.06 during the last trading session, reaching $2.85. About 2.20M shares traded. Genworth Financial, Inc. (NYSE:GNW) has risen 3.41% since February 23, 2017 and is uptrending. It has underperformed by 13.29% the S&P500.

Roosevelt Investment Group Inc, which manages about $2.79B and $1.09 billion US Long portfolio, decreased its stake in Exxon Mobil Corporation (NYSE:XOM) by 26,792 shares to 19,972 shares, valued at $1.64M in 2017Q3, according to the filing. It also reduced its holding in Facebook Inc (NASDAQ:FB) by 9,878 shares in the quarter, leaving it with 117,118 shares, and cut its stake in Edwards Lifesciences Corp (NYSE:EW).

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It increased, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. Moreover, Salem Inv Counselors Incorporated has 1.24% invested in Pfizer Inc. (NYSE:PFE) for 295,677 shares. Nationwide Fund Advsr stated it has 3.26 million shares or 0.46% of all its holdings. 134.30 million were accumulated by Bancorp Of America De. Cetera Ltd Liability holds 0.23% or 105,152 shares. Country Tru Bankshares accumulated 806,184 shares or 1.3% of the stock. Moreover, Cambridge Advsr Incorporated has 0.2% invested in Pfizer Inc. (NYSE:PFE). Texas Yale Cap reported 83,079 shares. Jolley Asset Mgmt Ltd Com owns 123,308 shares for 2.99% of their portfolio. Yhb Invest Advisors invested 0.86% in Pfizer Inc. (NYSE:PFE). Lloyds Group Inc Public Ltd Co accumulated 444 shares. Morgan Stanley holds 0.5% of its portfolio in Pfizer Inc. (NYSE:PFE) for 46.97M shares. First Wilshire Secs Mngmt Inc holds 0.11% of its portfolio in Pfizer Inc. (NYSE:PFE) for 10,926 shares. Cap Interest Sarl invested 0.09% in Pfizer Inc. (NYSE:PFE). 4.11M are held by Korea Corporation. Headinvest Limited Liability Com holds 0.33% or 30,281 shares in its portfolio.

Since August 31, 2017, it had 0 insider buys, and 7 insider sales for $12.30 million activity. $249,750 worth of Pfizer Inc. (NYSE:PFE) was sold by MACKENZIE ALEXANDER R on Friday, December 15. Another trade for 8,000 shares valued at $296,560 was sold by JOHNSON RADY A. $3.21M worth of stock was sold by DAMELIO FRANK A on Thursday, August 31. $1.34 million worth of Pfizer Inc. (NYSE:PFE) was sold by SUSMAN SALLY.

Among 22 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $39.85’s average target is 11.50% above currents $35.74 stock price. Pfizer had 74 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, October 28 the stock rating was maintained by Deutsche Bank with “Buy”. On Thursday, July 14 the stock rating was maintained by Jefferies with “Buy”. The firm earned “Sell” rating on Tuesday, May 16 by Citigroup. The firm earned “Market Perform” rating on Monday, May 2 by Leerink Swann. The stock of Pfizer Inc. (NYSE:PFE) earned “Neutral” rating by Societe Generale on Friday, March 24. The stock of Pfizer Inc. (NYSE:PFE) earned “Overweight” rating by Piper Jaffray on Friday, August 28. The rating was downgraded by Credit Suisse to “Neutral” on Thursday, July 20. The rating was initiated by Societe Generale on Wednesday, April 6 with “Hold”. The stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given on Friday, October 2 by Morgan Stanley. Piper Jaffray maintained it with “Overweight” rating and $48 target in Friday, August 28 report.

Saba Capital Management Lp, which manages about $7.93B and $986.86M US Long portfolio, upped its stake in Mbia Inc (Put) (NYSE:MBI) by 2.79M shares to 3.01M shares, valued at $27.20 million in 2017Q3, according to the filing. It also increased its holding in Community Health Sys Inc New (NYSE:CYH) by 58,419 shares in the quarter, for a total of 3.61M shares, and has risen its stake in Avon Prods Inc (NYSE:AVP).

Investors sentiment increased to 1.28 in Q3 2017. Its up 0.13, from 1.15 in 2017Q2. It improved, as 17 investors sold GNW shares while 77 reduced holdings. 44 funds opened positions while 76 raised stakes. 315.12 million shares or 4.07% less from 328.49 million shares in 2017Q2 were reported. Fmr Limited Liability Corporation owns 16.85M shares or 0.01% of their US portfolio. 31,778 were reported by Cubist Systematic Strategies Lc. Commerzbank Aktiengesellschaft Fi stated it has 0% of its portfolio in Genworth Financial, Inc. (NYSE:GNW). Zeke Cap Advsrs Ltd Liability holds 0.01% of its portfolio in Genworth Financial, Inc. (NYSE:GNW) for 16,264 shares. Schwab Charles Investment Mgmt accumulated 3.16M shares or 0.01% of the stock. Gabelli Funds Ltd Liability Com holds 0% or 26,568 shares. Royal Fincl Bank Of Canada holds 956,420 shares. Employees Retirement Association Of Colorado has invested 0% in Genworth Financial, Inc. (NYSE:GNW). Prudential Fincl holds 6.64M shares or 0.04% of its portfolio. Susquehanna Group Inc Limited Liability Partnership holds 1.12 million shares. Balyasny Asset Ltd Limited Liability Company accumulated 29,516 shares. Nomura Asset Mngmt owns 39,200 shares. Sei Invs has 0% invested in Genworth Financial, Inc. (NYSE:GNW). First Wilshire Secs Mngmt owns 821,578 shares for 0.9% of their portfolio. Moreover, Mariner Wealth Advisors Lc has 0.01% invested in Genworth Financial, Inc. (NYSE:GNW).

Among 8 analysts covering Genworth Financial (NYSE:GNW), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. Genworth Financial has $9 highest and $1.75 lowest target. $5.31’s average target is 86.32% above currents $2.85 stock price. Genworth Financial had 22 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, November 17 by Goldman Sachs. UBS maintained the shares of GNW in report on Tuesday, September 8 with “Neutral” rating. The firm has “Market Perform” rating by Wells Fargo given on Friday, September 23. As per Monday, February 8, the company rating was maintained by Compass Point. The firm has “Neutral” rating given on Wednesday, August 5 by Macquarie Research. The stock of Genworth Financial, Inc. (NYSE:GNW) earned “Hold” rating by Wells Fargo on Tuesday, August 1. UBS downgraded Genworth Financial, Inc. (NYSE:GNW) on Wednesday, November 4 to “Sell” rating. On Wednesday, October 5 the stock rating was downgraded by BTIG Research to “Neutral”. The stock of Genworth Financial, Inc. (NYSE:GNW) has “Buy” rating given on Friday, November 11 by Compass Point. Raymond James downgraded the stock to “Outperform” rating in Thursday, August 6 report.

Analysts await Genworth Financial, Inc. (NYSE:GNW) to report earnings on May, 1. They expect $0.23 earnings per share, down 20.69% or $0.06 from last year’s $0.29 per share. GNW’s profit will be $114.84M for 3.10 P/E if the $0.23 EPS becomes a reality. After $0.65 actual earnings per share reported by Genworth Financial, Inc. for the previous quarter, Wall Street now forecasts -64.62% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: